Document Detail


Anemia management and treatment response in patients on hemodialysis: the MAR study.
MedLine Citation:
PMID:  16874697     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: Anemia management guidelines describe the importance of anemia as a risk factor in hemodialysis and the need for clinical prospective studies focused on this role of anemia. Response to treatment with iron and epoetin is multifactorial, and results are still far from the targets set by the guidelines. The Morbidity and Mortality Anemia Renal study (MAR) is a multicenter prospective cohort study of hemodialysis (HD), designed to assess the burden of anemia on morbidity and mortality. We report here a cross-sectional analysis of the management of anemia, and response-to-treatment factors. METHODS: A total of 1,710 patients were included (60% male, mean age 64.4 +/- 13.6 years, mean 16.2 +/- 11.1 months on HD) with a high comorbidity (hypertension 75.8%, diabetes 25.9%, heart failure 13.9% and coronary disease 16.7%) and a mean Charlson Index of 6.5 +/- 2.3. RESULTS: There were 28.7% of patients who had started epoetin before end-stage renal disease (pre-ESRD), 81.4% of patients displayed Hb <11 g/dL when initiating HD with a mean Hb of 9.7 g/dL. Only 67.9% of prevalent HD patients attained a hemoglobin (Hb) level above 11 g/dL, 89.5% achieved a ferritin level above 100 ng/mL, 76.7% a transferrin saturation index (TSI) above 20%, and 61.1% met all 3 objectives. The multivariate analysis identified the following risk factors for Hb <11g/dL: low albumin (odds ratio, OR = 1.75), HD efficacy below objectives (OR = 1.44) and female sex (OR = 1.36), corrected for comorbidity, epoetin treatment, transfusion, surgery or hospital admission. CONCLUSIONS: As compared with previous surveys, we found an improved but still inadequate anemia management in Spanish HD patients. Our results are comparable with those of Euro-DOPPS. Several modifiable factors related to a lower Hb concentration were assessed. On behalf of the MAR Study Group.
Authors:
Jose Portolés; Juan Manuel López-Gómez; Pedro Aljama
Related Documents :
20056757 - Effect of different dialysis modalities on microinflammatory status and endothelial dam...
19622897 - Validation of arteriograph - a new oscillometric device to measure arterial stiffness i...
7738747 - Intestinal neuronal dysplasia is a possible cause of persistent bowel symptoms after pu...
18609507 - Effect of vitamin e-coated dialysis membranes on anemia in patients with chronic kidney...
9735647 - Appendicectomy and ulcerative colitis.
16118617 - Prognostic importance of haemostatic parameters in polyarterial disease.
Publication Detail:
Type:  Journal Article; Multicenter Study    
Journal Detail:
Title:  Journal of nephrology     Volume:  19     ISSN:  1121-8428     ISO Abbreviation:  J. Nephrol.     Publication Date:    2006 May-Jun
Date Detail:
Created Date:  2006-07-28     Completed Date:  2006-09-28     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9012268     Medline TA:  J Nephrol     Country:  Italy    
Other Details:
Languages:  eng     Pagination:  352-60     Citation Subset:  IM    
Affiliation:
Nephrology Service, Alcorcón Hospital Foundation, Madrid, Spain. jmportoles@fhlcorcon.es
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Aged
Anemia / drug therapy*,  epidemiology*
Cohort Studies
Cross-Sectional Studies
Epoetin Alfa / administration & dosage*
Female
Hematinics / administration & dosage*
Humans
Kidney Failure, Chronic / complications,  mortality*,  therapy
Male
Middle Aged
Renal Dialysis*
Spain / epidemiology
Chemical
Reg. No./Substance:
0/Hematinics; 113427-24-0/Epoetin Alfa

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Chronic periodontitis in hemodialysis patients with chronic kidney disease is associated with elevat...
Next Document:  Hodgkin's lymphoma with concurrent systemic amyloidosis, presenting as acute renal failure, followin...